AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
1. AstraZeneca paused a £200 million investment in Cambridge site. 2. The UK faces criticism for being unfriendly to pharma investments. 3. R&D investment in the UK declined since 2018, affecting competitiveness. 4. Foreign direct investment in UK life sciences dropped by 58% since 2017. 5. AstraZeneca's stock fell 2.46% to $77.60 following the news.